Tibulizumab showed promise in preclinical studies by demonstrating potent neutralization of BAFF and IL-17 (Benschop et al., 2019) and was previously considered for the treatment of RA (NCT01925157). The gene discussed is IL17A; the disease is rheumatoid arthritis.